Trials / Not Yet Recruiting
Not Yet RecruitingNCT06714370
Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 35 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to describe the real-world effectiveness and safety of tirabrutinib among relapsed or refractory PCNSL patients in Taiwan.
Conditions
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-12-03
- Last updated
- 2024-12-03
Source: ClinicalTrials.gov record NCT06714370. Inclusion in this directory is not an endorsement.